Latest Headlines

Latest Headlines

Novartis pins weak Jetrea sales on PhIII, KDEV CEO leaves after 3 months, Cantargia plans IPO

In this week's EuroBiotech Report, Belgian biotech ThromboGenics, having seen its stock price peak at €45 two years ago, has experienced a series of share slides, the latest of which was triggered by its partner Novartis. And more.

Diabetes devices drag down Abbott in Q4, but 2015 growth expected on FreeStyle Libre in EU

Abbott Laboratories' sales of medical devices slipped by 3.9% to $1.4 billion in the fourth quarter of 2014 over the same period a year earlier. The company is looking to gain traction in medical devices with its entrance into the electrophysiology market with the December completion of its Topera acquisition.

AnaMar rethinks pipeline after analyzing ashes of failed trial

AnaMar has rejigged its pipeline priorities after digging through the data from its failed Phase IIa trial. The trial missed its primary endpoint of reducing pain in people with mild to moderate osteoarthritis pain, but a post hoc subgroup analysis has persuaded AnaMar it was trialling the right drug in the wrong indication.

International regulators offer to help India build expertise

European regulators have joined the FDA in suggesting joint plant inspections and training with their Indian counterparts. The offers come as India's industry has lost status in recent years as the FDA and other countries have banned Indian plants from shipping to the U.S. and Europe over quality and data-integrity issues.

Basilea eyes blockbuster sales after antifungal gets FDA panel OK

After years of setbacks for the antibiotic ceftobiprole, Basilea Pharmaceutica's antifungal isavuconazole is now on the cusp of winning FDA approval. And Basilea thinks it and partner Astellas Pharma have a potential blockbuster on their hands.

Cantargia hits go on Swedish IPO

Cantargia is moving ahead with plans to list on Nasdaq First North in Stockholm, Sweden. The IPO is intended to give Cantargia the cash to push ahead with development of its lead candidate, an antibody-based cancer therapy that is on the cusp of entering the clinic.

Novartis points to PhIII data to explain weak Jetrea sales

Novartis has admitted that sales of the vitreomacular adhesion drug it licensed from ThromboGenics have failed to live up to expectations. And while various theories have been put forward to explain the drug's relative lack of commercial success, Novartis thinks part of the issue dates back to clinical trials.

Samsung Bioepis advances its Enbrel biosimilar to an EMA review

The Marketing Authorization Application for SB4, the Enbrel (etanercept) biosimilar candidate developed by Korean biopharmaceutical company Samsung Bioepis, has been validated and accepted for review by the European Medicines Agency. It will become the first Enbrel biosimilar subjected to regulatory review in the European Union.

Wall Street remains skeptical of Philips HealthTech refocus after Volcano buy

Investors sent Royal Philips down 5% after it disclosed its 2014 earnings report. Analysts on the call clearly remained unconvinced that the $1.2 billion acquisition of catheter-based imaging company Volcano announced in mid-December would help the company. It's in the midst of making the transition to being solely focused on HealthTech, a combination of healthcare and consumer businesses.

Siemens preps for healthcare spinoff with exec shuffle, but profits slide

Siemens reorganized its board and management in preparation for the long-planned spinoff of its healthcare business. The move comes as profits slip for the conglomerate's healthcare offerings, although revenues for the group continue to grow.